这一手笔刷新了外资药企在华投资纪录，尤其值得关注的是，这笔巨额投资重点投向了江苏的无锡与泰州。 要知道，阿斯利康并没有在中国多地"撒胡椒面"，而是把大部分筹码集中押在这两个地方，同时还联动青岛。 这背后，究竟是阿斯利康多大的野心？ 英国首相访华的同时，全球药企巨头阿斯利康向中国市场砸下了千亿级投资大单。 1月29日，阿斯利康宣布计划于2030年前在中国投资超1000亿元人民币，重点布局细胞治疗、放射偶联药物等领域。 阿斯利康"偏爱"无锡 早在1993年刚进入中国市场时，阿斯利康就把第一个"家"安在了无锡高新区。 2001年，它在中国的第一家工厂也在无锡建成，如今这不仅是阿斯利康在华的起点，更是其亚太地区最大、最核心的药品生产与包装基地。 此后，销售总部、物流中心、创新平台陆续落地，30多年来，无锡一步步从一个生产基地，成长为阿斯利康在中国集生产、分拨、销售、研发和创新于一 体的"全能型"总部。 很多人肯定想问阿斯利康为什么如此"偏爱"无锡？ 首先，无锡不是"白纸一张"，这里早有成熟的生物医药产业土壤。据官方数据显示，目前，无锡生物医药产业领域拥有6家世界500强、15家上市公司、近 500家规上企业，产业规模 ...

Group 1 - The core viewpoint is that AstraZeneca's CEO emphasizes China's indispensable role in the global pharmaceutical innovation ecosystem [1][2] - AstraZeneca plans to invest over 100 billion RMB in China by 2030, driven by the significant demand for drugs from Chinese patients and the country's strong innovation environment [1] - The company currently operates two global strategic R&D centers in Beijing and Shanghai, with multiple production bases in China supplying innovative medicines to over 70 markets worldwide [1] Group 2 - Future plans include establishing two new production bases in China focused on cell therapy and radiolabeled drugs, alongside increasing R&D investment and expanding the production network [1] - The CEO believes that UK-China collaboration in life sciences can benefit both nations and global patients through joint innovation, with significant potential in areas like green transformation and artificial intelligence [1][2]

Group 1 - AstraZeneca announced a significant investment plan of over 100 billion RMB (approximately 14 billion USD) in China by 2030, marking a record for foreign pharmaceutical companies in the country [1][2] - The investment aims to enhance AstraZeneca's drug production and research capabilities in China, reflecting the country's growing importance as a hub for scientific innovation and advanced manufacturing [2][5] - This strategic move is seen as a response to geopolitical tensions, emphasizing that healthy economic cooperation can stabilize international relations [2][5] Group 2 - The investment will cover the entire value chain from early drug discovery to large-scale production, with a focus on becoming the first multinational pharmaceutical company in China to have "end-to-end" cell therapy capabilities [2][5] - AstraZeneca's decision is driven by four unique advantages in China: a large and diverse patient population, a wealth of high-quality STEM talent, an encouraging regulatory environment, and a complete industrial chain [5] - The collaboration is expected to lead to the launch of 20 global innovative drugs in China by the end of 2030, improving access to cutting-edge treatments for patients [7][9] Group 3 - The investment signifies a shift in China's role from being merely an important market to a core strategic partner for multinational pharmaceutical companies [5] - AstraZeneca's commitment is anticipated to generate high-level technology and talent spillovers, enhancing China's position in the global pharmaceutical value chain [7] - The overarching message is that collaboration and openness are essential for addressing global challenges, with AstraZeneca's investment serving as a testament to the potential of working with China's innovative ecosystem [9]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030, indicating a strategic shift in its global innovation focus, positioning China as a key node in its global innovation system [6][9]. Investment Strategy - The investment spans the entire value chain from drug discovery to commercialization, focusing on cutting-edge areas like cell therapy and radiolabeled drugs, which are characterized by high technical barriers and competition [6][7]. - AstraZeneca is not merely investing in traditional chemical or mature biologics but is betting on disruptive technology platforms that have the potential to reshape treatment paradigms [7]. Local Collaboration - AstraZeneca's strategy involves deep integration into China's innovation network through partnerships with local biotech firms, exchanging capital and global capabilities for early-stage innovative assets [8]. - The acquisition of Gensight Biologics in 2024 positions AstraZeneca as one of the few multinational companies with end-to-end cell therapy capabilities in China, which is strategically valuable amid rising global regulatory and supply chain uncertainties [8]. R&D and Clinical Trials - The global strategic R&D centers in Beijing and Shanghai are now leading global clinical trials, reflecting China's increasing influence in the global new drug development process [9]. - Collaborations with over 500 clinical hospitals enhance AstraZeneca's advantages in real-world data and patient recruitment efficiency [9]. Manufacturing Expansion - AstraZeneca's manufacturing bases in Wuxi, Taizhou, Qingdao, and Beijing are not only serving the Chinese market but are also supplying to over 70 global markets, indicating a shift from being a part of the global pharmaceutical supply chain to becoming a multi-regional drug export center [9]. - The establishment of a multi-center, switchable production system is part of AstraZeneca's risk management strategy in light of geopolitical and regulatory uncertainties [9]. Employment and Industry Impact - AstraZeneca's workforce in China is expected to exceed 20,000, creating high-value jobs in R&D, clinical, engineering, and quality systems, indicating a shift in the strategic position of local teams within the company [9]. - This investment aligns with China's "Healthy China 2030" goal, reflecting a complex market that offers both policy certainty and innovative returns for multinational pharmaceutical companies [9].

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]

2026.01. 29 本文字数：898，阅读时长大约2分钟 作者 | 第一财经 钱童心 1月29日，在英国首相斯塔默访华期间，阿斯利康宣布，计划于2030年前在中国投资超过1000亿元 人民币，以扩大在药品生产与研发领域的布局。 这也是这家英国制药巨头对中国市场作出的最新承诺。公司称，最新的投资将充分发挥中国的科研优 势和先进制造能力，并依托中英医疗健康生态系统之间的协同合作，为中国及全球患者带来前沿创新 疗法。 去年3月，阿斯利康宣布了一项价值高达25亿美元的投资计划，将在北京建立全球第六个、中国第二 个战略研发中心，并达成多项重大研发与生产合作，以进一步推动中国生命科学事业发展。 阿斯利康全球首席执行官苏博科表示："今天宣布的这笔超过1000亿元人民币的重大投资，开启了 阿斯利康在华发展的新篇章。中国已成为科学创新、先进制造和全球公共卫生领域的重要力量。通过 进一步扩展我们在细胞治疗、放射偶联药物等突破性疗法的能力，阿斯利康将为中国高质量发展作出 更大贡献，更重要的是，把下一代创新疗法带给更多患者。" 中国在新疗法领域拥有前沿科学。据介绍，这些投资将覆盖从药物发现、临床开发到生产制造的完整 价值链，将中 ...

(投资中国)2030年前阿斯利康拟在华投资超1000亿元 该项投资在英国首相访华期间宣布，阿斯利康表示，这将进一步加强英中在医疗健康创新领域的合作， 并惠及两国的生命科学生态系统。(完) 来源：中国新闻网 编辑：郭晋嘉 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 中新社北京1月29日电 (记者 尹倩芸 迟瀚宇)全球医药巨头阿斯利康29日宣布，计划于2030年前在中国投 资逾1000亿元人民币(150亿美元)，以扩大在药品生产与研发领域的布局。 阿斯利康全球首席执行官苏博科(Pascal Soriot)表示，中国已成为科学创新、先进制造和全球公共卫生领 域的重要力量。通过进一步扩展细胞治疗、放射偶联药物等突破性疗法的能力，阿斯利康将把下一代创 新疗法带给更多患者。 阿斯利康表示，该项投资将显著增强公司在细胞治疗和放射偶联药物方面的能力，推动公司广泛多元化 产品管线发展，惠及癌症、血液病和自身免疫性疾病等患者。 据悉，这些 ...

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to enhance its drug production and R&D capabilities, leveraging China's scientific research strengths and advanced manufacturing [1][3] Group 1: Investment Details - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, aiming to bring China's innovative results to a global audience [3] - AstraZeneca's CEO highlighted that this investment marks a new chapter in the company's development in China, recognizing the country as a significant force in scientific innovation and global public health [3] Group 2: Strategic Initiatives - The investment will significantly enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline that benefits patients with cancer, blood diseases, and autoimmune disorders [3] - AstraZeneca aims to become the first multinational pharmaceutical company with end-to-end cell therapy capabilities in China [3] Group 3: Previous Investments - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - As of January this year, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [3]